It was found that IAA could reduce Th17 cell production by activating the aromatic hydrocarbon receptor (AhR) and down-regulating RORγt and STAT3 (Su et al., 2022), suggesting that IAA has the potential to be a targeted drug for the treatment of ITP. This evidence concerns the gene AHR and autoimmune thrombocytopenic purpura.